Clinical Trials Logo

Filter by:
NCT ID: NCT03546166 Completed - Carcinoma Clinical Trials

Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma

PICABAS
Start date: July 26, 2018
Phase: Phase 2
Study type: Interventional

Basal cell carcinomas (BCCs) are the most common form of cancer. The treatment of BCC can be surgical or topical for the low-risk subtypes. Topical treatments used for BCC are imiquimod and photodynamic therapy (PDT). Ingenol mebutate could provide a fast and easy topical therapy for BCC. Data regarding the treatment of BCC with ingenol mebutate are still limited. The investigators propose a pilot study to investigate the efficacy of 1 or 2 courses of ingenol mebutate 0,05%, on superficial and nodular BCC

NCT ID: NCT03546127 Completed - Soft Tissue Sarcoma Clinical Trials

Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study

MULTIPLI-0
Start date: May 23, 2017
Phase:
Study type: Observational

Next Generation Sequencing in cancer: a feasibility study in France to assess sample circuit and to perform analyzes within a limited time.

NCT ID: NCT03545776 Completed - Clinical trials for Intensive Care Units

Critical Care EEG Course

Start date: May 22, 2018
Phase:
Study type: Observational

Knowledge of the basic fundamental skills of electroencephalography would enable medical and nursing staffs to provide efficient and effective bedside EEG monitoring in critically ill patients. The aim of this study is to evaluate the ability of a 10-points EEG teaching program to allow bedside caregivers (medical and nursing intensive care unit staff) interpreting EEG in the critical care setting.

NCT ID: NCT03545529 Completed - Fall Patients Clinical Trials

Clinical and Medico-economic Evaluation of the Cohort "People at Risk of Falling"

PARC
Start date: February 16, 2018
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the effectiveness of the IsereADOM service package compared to conventional follow-up on the risk of recurrence of falls at 6 months in frail elderly subjects. There is a medico-economic goal too, is to conduct a cost-utility analysis of the IsereADOM service bundle compared to conventional 6-month follow-up from the community perspective in the cheat population at risk of re-offending.

NCT ID: NCT03545308 Completed - Clinical trials for Neuromuscular Blockade

Pharmacokinetics of Rocuronium for Deep Block (DeepRocu)

DeepRocu
Start date: August 25, 2017
Phase:
Study type: Observational

Rocuronium is a non-depolarising neuromuscular blocking agent. The compound has a rapid onset and an intermediate duration of action. The rapid onset is of importance in patients at risk for pulmonary aspiration, for elective induction of anesthesia. Clinical studies simulating rapid sequence induction in elective patients indicate that rocuronium 0.9 mg kg-1 may be suitable for crash intubation.Also, rocuronium may be an alternative to succinylcholine for rapid sequence induction when high dose is injected (3x Effective Dose 95 %= 1mg/kg). But, pharmacokinetic of rocuronium at 1 mg/kg is not well establish. The investigator investigate the onset and recovery of a single dose rocuronium (1 mg/kg) in consecutive patients (>100) using adductor muscle monitoring (Train of Four and Post Tetanic Count)

NCT ID: NCT03544957 Completed - Clinical trials for Elderly Subject Fragility

Evaluation of the Triage Risk Screening Tool

TRST-U
Start date: October 1, 2018
Phase:
Study type: Observational

This study tried to describe diagnostic properties of TRST completed by an emergency doctor, for screening process for fragility of elderly subjects admitted at the accident and emergency department.

NCT ID: NCT03544203 Completed - Clinical trials for Intraabdominal Infections

Multicentre Observational Study on Community Acquired Intraabdominal Infections Management

PERICOM
Start date: April 1, 2018
Phase:
Study type: Observational

Intraabdominal infection require rapid care management including antibiotic therapy and source control. Morbidity and mortality associated with Intraabdominal infections remain high. French recommendations have been edited in 2000 further updated in 2014. Delay in diagnosis and surgery can lead to worsened outcomes. However, little data are available on early community-acquired intraabdominal infections management to identify risk factors of inadequate management.

NCT ID: NCT03543956 Completed - Systemic Sclerosis Clinical Trials

Professional and Personal Toxic Exposure in Systemic Sclerosis : Type, Intensity and Probability of Exposition

VISSEXPOSITION
Start date: June 4, 2018
Phase:
Study type: Observational

Systemic Sclerosis (SSc) is an inflammatory chronic disease that can lead to structural damage and handicap. The SSc physiopathology is multifactorial, including genetic and environmental risk factors. The identification of environmental factors implication is crucial to understand the SSc mechanism, and improves the diagnosis and the treatment of the disease.

NCT ID: NCT03543436 Completed - Clinical trials for Urinary Tract Infections

Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections

TEMO-CARB
Start date: January 4, 2019
Phase: Phase 3
Study type: Interventional

TEMO-CARB is a phase 3, randomized, controlled, multicentre, open-label pragmatic clinical trial to test the non-inferiority of temocillin versus carbapenem as initial intravenous treatment of Urinary Tract Infection (UTI) due to extended-spectrum beta-lactamase (ESBL) producing enterobacteriaceae.

NCT ID: NCT03541213 Completed - Iron-deficiency Clinical Trials

Impact of Iron Deficiency and Its Correction on Mitochondrial Metabolism of the Cardiomyocyte (MitoCardioFer)

MitoCardioFer
Start date: January 23, 2019
Phase: N/A
Study type: Interventional

Iron is involved in essential functions of the body. It allows the transport of oxygen in the blood, via hemoglobin, at the muscular level, via myoglobin, and it is also involved in cellular metabolism in general, in particular for the production of ATP at the mitochondrial level, within the cytochromes and iron-sulfur proteins of the respiratory chain. Recently, iron deficiency has been identified as an important prognostic factor in heart failure patients. Iron therapy improves symptoms and physical performances of heart failure patients, even in the absence of anemia. As a result, the correction of iron deficiency is now proposed as one of the therapies for heart failure. However, the pathophysiology of the association between cardiac dysfunction and iron deficiency is still poorly understood. The investigators previously developed a mouse model of iron deficiency without anemia, in which the investigators observed impaired physical performances, a decrease of left ventricular ejection fraction, and a decrease in mitochondrial complex I activity. These abnormalities were normalized after iron injection. These animal data suggest that iron deficiency is responsible for left ventricular dysfunction secondary to mitochondrial I complex abnormalities, and that iron therapy corrects them. Iron deficiency is very common in the preoperative period of cardiac surgery, affecting 40 to 50% of patients. During this surgery, it is possible to perform a myocardial biopsy without risk to the patient. The purpose of this study is to verify in patients requiring valvular heart surgery, if iron deficiency is responsible for a decrease in mitochondrial complex I activity and a decrease in cardiac function during the perioperative period, and to verify whether iron treatment improves these abnormalities.